Skip to main content

Main menu

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

User menu

  • Log in
  • Subscribe
  • Contact Us
  • My Cart

Search

  • Advanced search
  • ERS Publications
    • European Respiratory Journal
    • ERJ Open Research
    • European Respiratory Review
    • Breathe
    • ERS Books
    • ERS publications home

Login

European Respiratory Society

Advanced Search

  • Home
  • Current issue
  • ERJ Early View
  • Past issues
  • Authors/reviewers
    • Instructions for authors
    • Submit a manuscript
    • Open access
    • COVID-19 submission information
    • Peer reviewer login
  • Alerts
  • Podcasts
  • Subscriptions

Methotrexate treatment in recent onset RA does not change the NO dynamics of the lung

Marieann Högman, Anders Lind, Anders Larsson, Johan Rönnelid, Tomas Weitoft
European Respiratory Journal 2021 58: PA3720; DOI: 10.1183/13993003.congress-2021.PA3720
Marieann Högman
1Dept of Medical Science, Uppsala Univeristy, Uppsala, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: marieann.hogman@medsci.uu.se
Anders Lind
2Centre for Research and Development, Uppsala University/ Region Gävleborg, Gävle, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Anders Larsson
3Dept of Medical Science, Uppsala University, Uppsala, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Johan Rönnelid
4Dept of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tomas Weitoft
2Centre for Research and Development, Uppsala University/ Region Gävleborg, Gävle, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Abstract

Patients with established rheumatoid arthritis (RA) and recent onset RA have lower nitric oxide (NO) levels in the alveolar compartment (CANO) and in the airway wall (CawNO), but also a higher diffusion capacity for NO in the airways (DawNO) compared with matched controls. The aim was to study recent onset RA subjects, before treatment and 3 months of immunosuppressive treatment with methotrexate (MTX).

RA subjects, ACPA positive, were recruited. Disease activity was measured using Disease Activity Score for 28 joints (DAS28), and disability according to Health Assessment Questionnaire (HAQ). The NO dynamics (median (IQR)) were estimated by the Högman-Meriläinen algorithm.

When the non-smoking RA subjects (n=22) were compared with smoking subjects (n=8) there were differences in FENO50 of 19 (12, 25) ppb and 9 (5, 14) ppb resp. (p=0.004) and in NO dynamics CANO 2.1 (1.1, 2.3) ppb and 0.9 (0.3, 1.2) ppb resp. (p=0.007), while no differences were found in CawNO 65 (38, 119) ppb and 21 (17, 61) ppb resp. (p=0.12), and DawNO 16 (8, 31) mL/s and 17 (8, 27) mL/s resp. (p=0.68). The weekly MTX dose was 20 (15, 20) mg. There were reductions of DAS28, HAQ and s-CRP on MTX treatment with no differences between non-smokers and current smokers. Neither FENO50 nor any of the NO parameters changed after MTX. There were no correlations between FENO50 and NO parameters with DAS28, HAQ and s-CRP before or after treatment.

The altered NO dynamics of the lung in ACPA positive RA patients are present in the early stage of the disease, before any treatments are initiated and do not change after MTX therapy. The HMA can be an additional tool to study the early pulmonary events in the development of the RA pathology.

  • Nitric oxide
  • Monitoring
  • Immunosuppression

Footnotes

Cite this article as: European Respiratory Journal 2021; 58: Suppl. 65, PA3720.

This abstract was presented at the 2021 ERS International Congress, in session “Prediction of exacerbations in patients with COPD”.

This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).

  • Copyright ©the authors 2021
Previous
Back to top
Vol 58 Issue suppl 65 Table of Contents
  • Table of Contents
  • Index by author
Email

Thank you for your interest in spreading the word on European Respiratory Society .

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Methotrexate treatment in recent onset RA does not change the NO dynamics of the lung
(Your Name) has sent you a message from European Respiratory Society
(Your Name) thought you would like to see the European Respiratory Society web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Methotrexate treatment in recent onset RA does not change the NO dynamics of the lung
Marieann Högman, Anders Lind, Anders Larsson, Johan Rönnelid, Tomas Weitoft
European Respiratory Journal Sep 2021, 58 (suppl 65) PA3720; DOI: 10.1183/13993003.congress-2021.PA3720

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Methotrexate treatment in recent onset RA does not change the NO dynamics of the lung
Marieann Högman, Anders Lind, Anders Larsson, Johan Rönnelid, Tomas Weitoft
European Respiratory Journal Sep 2021, 58 (suppl 65) PA3720; DOI: 10.1183/13993003.congress-2021.PA3720
del.icio.us logo Digg logo Reddit logo Technorati logo Twitter logo CiteULike logo Connotea logo Facebook logo Google logo Mendeley logo

Jump To

  • Article
  • Info & Metrics
  • Tweet Widget
  • Facebook Like
  • Google Plus One

More in this TOC Section

  • Late Breaking Abstract - The SF-36 quality of life scales are sensitive measures of lung function decline
  • Usefullnes of chest computed tomography as a tool to predict COPD exacerbations
  • Late Breaking Abstract - Adrenal function improvement after oral corticosteroid reduction in benralizumab-treated severe eosinophilic asthma: PONENTE maintenance phase
Show more Monitoring airway disease

Related Articles

Navigate

  • Home
  • Current issue
  • Archive

About the ERJ

  • Journal information
  • Editorial board
  • Reviewers
  • Press
  • Permissions and reprints
  • Advertising

The European Respiratory Society

  • Society home
  • myERS
  • Privacy policy
  • Accessibility

ERS publications

  • European Respiratory Journal
  • ERJ Open Research
  • European Respiratory Review
  • Breathe
  • ERS books online
  • ERS Bookshop

Help

  • Feedback

For authors

  • Instructions for authors
  • Publication ethics and malpractice
  • Submit a manuscript

For readers

  • Alerts
  • Subjects
  • Podcasts
  • RSS

Subscriptions

  • Accessing the ERS publications

Contact us

European Respiratory Society
442 Glossop Road
Sheffield S10 2PX
United Kingdom
Tel: +44 114 2672860
Email: journals@ersnet.org

ISSN

Print ISSN:  0903-1936
Online ISSN: 1399-3003

Copyright © 2022 by the European Respiratory Society